AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$ALNY

Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”

Alnylam Pharmaceuticals (ALNY) shares fell 19% after expanding its nucresiran heart trial to 2,250 patients, citing confidence in positive results. Despite 52% product revenue growth, concerns arise about nucresiran's benefit. Analysts expect revenue growth through 2028, driven by AMVUTTRA. Competitors like Pfizer (PFE) and BridgeBio (BBIO) may gain if nucresiran's data is weak.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 4:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction” — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ALNYBearishMed
01

Why it matters

The trial expansion signals potential efficacy concerns, prompting a sharp sell‑off. The move underscores the risk inherent in late‑stage biotech trials.

02

Market read

The news directly affects Alnylam's stock price and may influence sentiment toward RNA‑based cardiovascular therapies.

03

What to watch

Alnylam's strong product revenue growth and AMVUTTRA performance may cushion longer‑term valuation.

Relevance 7/10Novelty 8/10Timing: same-day reaction

Background

Alnylam reported a 52% rise in product revenue, driven by its approved drug AMVUTTRA, while expanding its experimental heart drug trial for the second time this year.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Alnylam shares fell 19% after the company announced a second expansion of its Phase 3 nucresiran heart trial, raising concerns about the drug's efficacy.

Expected impact

likely continued downside as investors reassess the drug's upside potential

Evidence & confidence

The 19% drop reflects market reaction to the trial change; no new positive data offset the concern.

Market effects

Sector

Other heart‑failure therapeutics may see modest upside as competitors could benefit if Alnylam's trial underperforms.

Regional

US biotech sector faces slight pressure from the news, but broader market impact is limited.

Global

Limited to investors tracking RNA‑based cardiovascular drugs.

Counterpoint

What could challenge this read

If the trial still meets its primary endpoint, the stock could rebound sharply on a positive readout.

Key entities

  • company
    Alnylam Pharmaceuticals

    US‑listed biotech developing nucresiran and AMVUTTRA.

Read at source← All news

StoryAlnylam Reports Q3 Growth, Expands Nucresiran Trial as Adoption Concerns Weigh

Also covered by

4 outlets

Related articles

OCT 29
$ALNYMed

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals reported that AMVUTTRA has access for 99% of covered lives, with 90% of patients within 10 miles of treatment. The company is monitoring a proposed CMS rule that could reduce Medicare reimbursement for 340B drugs, which represents a meaningful portion of its business. UnitedHealth implemented a restrictive policy for AMVUTTRA, potentially delaying access for new patients.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

fool.com3 min
OCT 29
$ALNYHighAI 8/10

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 revenue growth of 16.7% to $1.458 billion, driven by a 52% increase in global net product revenue, primarily from its TTR franchise. Net income rose to $2.167 billion. The company expanded its Phase 3 study for nucresiran and presented promising early data for brezosiran in Huntington's disease. Alnylam also advanced its pipeline with mivelsiran and ALN-5288 for neurological diseases.

rttnews.com3 min
OCT 29
$ALNYMedAI 8/10

Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook

Alnylam Pharmaceuticals (ALNY) updated its Phase 3 TRITON-CM study for nucresiran, expanding enrollment to 2,250 patients. The company aims for a 2030 launch, viewing it as key to long-term growth. Alnylam reaffirmed its FY26 outlook: $4.7B-$5.1B in product revenue, $575M-$625M in collaboration revenue, and $2.7B-$2.8B in R&D/SG&A expenses. ALNY stock fell 17.89% to $190.71.

rttnews.com1 min
OCT 29
$ALNYMed

Stifel downgrades Alnylam stock rating on Amvuttra concerns

Stifel downgraded Alnylam Pharmaceuticals (ALNY) to Hold from Buy, lowering its price target to $225 from $318. The firm cited concerns about Amvuttra's near-term performance and market challenges. Despite a strong Q3 2026 earnings beat, ALNY's stock fell due to guidance concerns and slower TTR franchise growth. The stock is near its 52-week low of $197.81, with a 79.7% gross profit margin.

investing.com2 min